Abstract 2256P
Background
In this study, we aimed to investigate the microenvironment of normal mucosa to predict prognosis of stage II/III colorectal cancer (CRC), after surgery.
Methods
We divide the groups using transcriptome sequencing data of prospectively collected tumors and paired normal tissue, obtained from the margins of the resected specimens from 111 patients at Samsung medical center. Groups were defined as follows: tumor-like microenvironment in normal mucosa group (tNME): high tumor signature in normal mucosa; normal microenvironment group (NME): low tumor signature in normal mucosa. The impact of this classification was further evaluated in two independent cohorts (Korean multi-center cohort and TCGA cohort). The microbial, and biological differences between groups were investigated based on 16s rRNA metagenomics and single-cell RNA sequencing.
Results
A total of 38 (34%) were classified as tNME. There were no significant differences in age, sex, TNM stage and CMS between subgroups. With a median follow-up of 57.9 months, tNME showed poorer 3-year recurrence-free survival (RFS) (56.0 % vs. 78.9 %, P=0.008) and 3-year overall survival (OS) (79.0 %vs. 87.7%, P=0.095) compared to NME. These were validated in the Korean multi-center validation cohort (3-year RFS: 55.3% vs. 74.5%, P=0.045), and TCGA cohort (3-year OS: 62.2% vs. 91.7%, P=0.071). Metagenomics exhibited a significantly lower proportion of carcinogenic genus including Fusobacterium, Bacteroides in normal of NME. There were significant differences in beta diversity between tumor and normal in NME, while no significant differences were noted in tNME, which suggests the feature of bacterial biofilm. PathSeq-based computational method of single-cell RNA sequencing revealed more proportion of infected cancer cells in tNME. EMP1 +epithelial cells were correlated with recurrence, and more proportion of this cluster, along with GZMK high CD8 T cells, inflammatory cancer-associated fibroblasts were noted in tumor of tNME, while more proportion of neutrophil was noted in normal of tNME.
Conclusions
The microenvironment of normal mucosa status could be a prognostic biomarker for CRC. The bacterial biofilm with weak intestinal barrier were related to tNME.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Bio & Medical Technology Development Program of the National Research Foundation funded by the Ministry of Science & ICT (grant no. NRF2017M3A9A7050803.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2305P - Next-generation sequencing-based regression algorithm to determine homologous recombination deficiency scores in a pan-cancer cohort
Presenter: Sejin Kim
Session: Poster session 08
2306P - How TAILORx changed treatment allocation based on 21-gene recurrence score in the daily clinic: A single center retrospective analysis
Presenter: Elena Chiru
Session: Poster session 08
2307P - Loss of CYP2D6 activity sensitizes liver cancer cells to chemotherapy
Presenter: Natallia Rameika
Session: Poster session 08
2308P - CyPep-1 reprograms the tumor microenvironment and enhances the efficacy of immune checkpoint inhibitors
Presenter: Bassam Janji
Session: Poster session 08
2309P - High DDR1 mRNA and protein expression across human tumor types correlate with epithelial composition of the tumor microenvironment
Presenter: Laura Dillon
Session: Poster session 08
2310P - Oxygen nano-bubbles attenuate hypoxia-induced tumour malignancy in tumour xenograft models
Presenter: Kumari Bhavya
Session: Poster session 08
2311P - Population pharmacokinetic-pharmacodynamic modeling to inform optimal dosing strategies for GI-101, a novel fusion protein, targeting IL2βγR and CTLA4
Presenter: Dongwoo Chae
Session: Poster session 08
2312P - SGLT2i dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity
Presenter: Annamaria Bonelli
Session: Poster session 08
2313P - APOBEC mutagenesis and macrophage infiltration in cancer
Presenter: Andrea Gazzo
Session: Poster session 08
2314P - Quality and safety of research biopsies (RB) in oncology clinical trials
Presenter: Paolo Nuciforo
Session: Poster session 08